- Home
- MLAB
as of 03-26-2026 1:40pm EST
Mesa Laboratories Inc manufactures life sciences tools and critical quality control products. It operates in four divisions: Sterilization and Disinfection Control, which manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization, decontamination, disinfection, and cleaning processes. Clinical Genomics division develops, manufactures, and sells highly sensitive, low-cost, high-throughput genetic analysis tools and related consumables. The Biopharmaceutical Development division develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. The Calibration Solutions division develops, manufactures, sells, and services quality control products.
| Founded: | 1982 | Country: | United States |
| Employees: | N/A | City: | LAKEWOOD |
| Market Cap: | 442.0M | IPO Year: | 1995 |
| Target Price: | $94.00 | AVG Volume (30 days): | 114.2K |
| Analyst Decision: | Hold | Number of Analysts: | 1 |
| Dividend Yield: | Dividend Payout Frequency: | annual | |
| EPS: | 1.95 | EPS Growth: | 99.24 |
| 52 Week Low/High: | $59.63 - $128.55 | Next Earning Date: | 02-03-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | 6.07% | Revenue Growth (next year): | 5.41% |
| P/E Ratio: | 42.87 | Index: | N/A |
| Free Cash Flow: | 42.6M | FCF Growth: | -11.76% |
AI-Powered MLAB Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Mesa Laboratories Inc. (MLAB)
Director
Avg Cost/Share
$76.35
Shares
1,301
Total Value
$99,331.35
Owned After
3,429
SEC Form 4
Director
Avg Cost/Share
$76.00
Shares
1,315
Total Value
$99,940.00
Owned After
5,398
SEC Form 4
Director
Avg Cost/Share
$72.23
Shares
3,500
Total Value
$252,805.00
Owned After
8,523
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Capone Mark Christopher | MLAB | Director | Mar 10, 2026 | Buy | $76.35 | 1,301 | $99,331.35 | 3,429 | |
| Tripeny R Tony | MLAB | Director | Mar 10, 2026 | Buy | $76.00 | 1,315 | $99,940.00 | 5,398 | |
| Ladiwala Shiraz Shabanali | MLAB | Director | Mar 10, 2026 | Buy | $72.23 | 3,500 | $252,805.00 | 8,523 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K BUY Feb 3, 2026 · 100% conf.
Q4 2025 Earnings
8-K BUYFeb 3, 2026 · 100% conf.
1D
+4.06%
$91.08
Act: +4.57%
5D
+8.10%
$94.62
Act: +5.05%
20D
+7.70%
$94.27
Act: +6.06%
mlab20260202_8k.htm
false 0000724004
0000724004
2026-02-03 2026-02-03
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 3, 2026
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Colorado
0-11740
84-0872291
(State or other jurisdiction of
incorporation) (Commission File Number) (I.R.S. Employer
Identification No.)
12100 West Sixth Avenue,
Lakewood, Colorado
(Address of principal executive offices)
80228
(Zip Code)
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which
registered
Common Stock, no par value
MLAB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On February 3, 2026, Mesa Laboratories, Inc. issued a press release relating to its results for the three and nine months ended December 31, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits:
99.1
Press release dated February 3, 2026.
104
Cover Page Interactive Data File (embedded withing the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: February 3, 2026
Mesa Laboratories, Inc.
(Registrant)
BY:
/s/ Gary M. Owens
Gary M. Owens
President and Chief Executive Officer
2025 Q3 Q3 2025 Earnings
8-K Nov 6, 2025
Q3 2025 Earnings
8-KNov 6, 2025
mlab20251106_8k.htm
false 0000724004
0000724004
2025-11-06 2025-11-06
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): NOVEMBER 6, 2025
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
colorado
(State or other jurisdiction of
incorporation)
0-11740
(Commission File Number)
84-0872291
(I.R.S. Employer
Identification No.)
12100 west sixth avenue,
lakewood, colorado
(Address of principal executive offices)
80228
(Zip Code)
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which
registered
Common Stock, no par value
MLAB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On November 6, 2025, Mesa Laboratories, Inc. issued a press release relating to its results for the three and six months ended September 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits:
99.1
Press release dated November 6, 2025.
104
Cover Page Interactive Data File (embedded withing the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: November 6, 2025
Mesa Laboratories, Inc.
(Registrant)
BY:
/s/ Gary M. Owens
Gary M. Owens
President and Chief Executive Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 5, 2025
Q2 2025 Earnings
8-KAug 5, 2025
mlab20250804_8k.htm
false 0000724004
0000724004
2025-08-05 2025-08-05
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): AUGUST 5, 2025
MESA LABORATORIES, INC.
(Exact name of registrant as specified in its charter)
Colorado
(State or other jurisdiction of
incorporation)
0-11740
(Commission File Number)
84-0872291
(I.R.S. Employer
Identification No.)
12100 WEST SIXTH AVENUE,
LAKEWOOD, Colorado
(Address of principal executive offices)
80228
(Zip Code)
Registrant’s telephone number, including area code: 303-987-8000
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered under Section 12(b) of the Act:
Title of each class
Trading Symbol
Name of each exchange on which
registered
Common Stock, no par value
MLAB
The Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
ITEM 2.02
RESULTS OF OPERATIONS AND FINANCIAL CONDITION
On August 5, 2025, Mesa Laboratories, Inc. issued a press release relating to its results for the three months ended June 30, 2025. A copy of the press release is furnished herewith as Exhibit 99.1.
The information furnished in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liabilities of that section, and shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended.
ITEM 9.01
FINANCIAL STATEMENTS AND EXHIBITS
(d)
Exhibits:
99.1
Press release dated August 5, 2025.
104
Cover Page Interactive Data File (embedded withing the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
DATE: August 5, 2025
Mesa Laboratories, Inc.
(Registrant)
BY:
/s/ Gary M. Owens
Gary M. Owens
President and Chief Executive Officer
Compare MLAB vs Leading Stocks
See how MLAB stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "MLAB Mesa Laboratories Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.